At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hendrik-Tobias Arkenau, MD, PhD, of Sarah Cannon Research Institute, UK, explains that the development of immunotherapies for a variety of cancer types and specific cancer proteins is a very active area of research at Sarah Cannon Research Institute.
New trials for cancer patients at Sarah Cannon Research Institute
9th February 2018
Oncology
Rate this content's potential impact on patient outcomes
Thank you!
Please share some more information on the rating you have given